BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 15807856)

  • 1. Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587.
    Li B; Wang Y; Chen J; Wu H; Chen W
    Clin Exp Immunol; 2005 May; 140(2):310-9. PubMed ID: 15807856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
    Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
    Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
    Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
    Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
    Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
    Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
    Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells.
    Li B; He X; Pang X; Zhang H; Chen J; Chen W
    Scand J Immunol; 2004 Nov; 60(5):506-13. PubMed ID: 15541044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design.
    Zhang J; Yang J; Fan D; Tao H; Wang H; Yu T
    Oncol Rep; 2013 May; 29(5):1955-61. PubMed ID: 23503586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
    Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
    Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
    Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
    Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma.
    Wu ZY; Gao YF; Wu YH; Liu W; Sun M; Zhai MX; Qi YM; Ye Y
    Scand J Immunol; 2011 Dec; 74(6):561-7. PubMed ID: 21815906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Estimation of an NY-ESO-1 expressing HCC cell line by NY-ESO-1b specific CD8+T cells in vitro induced by HLA-A2 restricted NY-ESO-1b peptide].
    Qiao H; Qian XP; Zhang HG; Tian C; Chen WF
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):565-8. PubMed ID: 16378102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
    Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
    Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL; Sui YF; Li ZS; Qu P; Wu W; Ye J; Zhang XM; Lu SY
    Cancer Lett; 2004 Aug; 211(2):219-25. PubMed ID: 15219945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a new MAGE-A10 antigenic peptide presented by HLA-A*0201 on tumor cells.
    Jia ZC; Tian Y; Huang ZM; Wang JX; Fu XL; Ni B; Wu YZ
    Cancer Biol Ther; 2011 Feb; 11(4):395-400. PubMed ID: 21124073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.